Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 10'th Nov 2025
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.
07:32am, Monday, 10'th Nov 2025
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.
Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle
04:38am, Monday, 10'th Nov 2025
Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.
U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer
03:45am, Monday, 10'th Nov 2025
The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will
Novo Nordisk shares rise after dropping Metsera bid
03:05am, Monday, 10'th Nov 2025
Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its bid for U.S. weight loss drug company Metsera, ending a bidding war with rival Pfizer.
Norway's sovereign wealth fund to abstain from Novo Nordisk board vote
02:37am, Monday, 10'th Nov 2025
Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk's extraordinary shareholders' meeting schedul
Novo Nordisk to sell weight loss drug Poviztra in India
01:04am, Monday, 10'th Nov 2025
Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra semaglutide injection in the country, the Indian firm said on Monday.
Wall Street Brunch: Here Come The 13Fs
01:31pm, Sunday, 09'th Nov 2025
13F filings this week will reveal hedge fund and institutional moves, offering insight into smart money positioning amid recent market highs. Earnings season is winding down, with 90% of S&P 500 compa
Virtus SGA Global Growth Q3 2025 Portfolio Positioning
01:01pm, Sunday, 09'th Nov 2025
We reviewed and maintained our UnitedHealth position through its underwriting crisis, recognizing that management's mispricing of annually renewable policies could be corrected through swift action. O
Novo Nordisk: Hold On Tightly As The Market Tests Your Faith
09:00am, Sunday, 09'th Nov 2025
Novo Nordisk faces persistent investor skepticism due to competitive pressures from Eli Lilly and repeated downward guidance revisions. NVO's recent management changes and strategic revamp aim to rest
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump
05:31am, Sunday, 09'th Nov 2025
Eli Lilly (LLY 1.39%) and Novo Nordisk (NVO 1.89%) agreed to lower prices for their weight loss treatments in exchange for lower tariffs and expanded access.
Should You Buy Novo Nordisk After the Huge Investor Update?
05:02am, Sunday, 09'th Nov 2025
Novo Nordisk (NVO 1.89%) is struggling with competition in its weight loss treatment business and is looking to make an acquisition to bolster its pipeline of drugs.
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
03:19am, Saturday, 08'th Nov 2025
Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera. On 30 October 2025, Novo Nordisk announced the submission
Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
03:29pm, Friday, 07'th Nov 2025
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs. Medicare will start covering GLP-1s
